What is needed to enhance Japan's drug discovery capabilities
The decline in Japan's pharmaceutical development, or so-called "drug discovery" capabilities, has become a major issue in recent years. While Japan was once known as a global hub for new drug development, there have been ongoing concerns that its competitiveness is waning.
According to expert analysis, it is not the case that Japan lacks "drug discovery seeds"—the foundations for new medicines. Numerous excellent research results are produced daily at universities and research institutions. However, it is believed that there is a problem in the process of turning those results into actual drugs that reach patients.
The biggest challenge at present lies in the design during the initial stages of research. Research findings are not being sufficiently "refined" for companies and investors to correctly evaluate them and establish them as viable businesses. To translate excellent technology into practical application, a system where researchers and business experts collaborate to develop strategies from the early stages is essential.
To strengthen Japan's drug discovery capabilities once again, a new framework is needed to implement research results into society. Moving forward, building a system to accurately communicate the value of research and attract investment will determine the future of Japan's medical industry.